Cancer treatment has changed over the last few decades as scientists are now using precision medicine. By using precision medicine, researchers have a better understanding of tumor biology of each individual patient. With the understanding, the researchers are accurately defining the prognosis of each given cancer and hence designing targeted treatment for specific molecular alterations. In several journals published on Oncotarget, it is clear that scientists are concentrating on molecular features and characteristics specific to cancer tissues to come up with medication that has minimal effect on healthy tissues.
Breast Cancer Treatment
One of the major milestones achieved by precision medicine is the understanding the biology of breast cancer. This type of cancer is complex and is characterized by diverse tumors and multiple types of the disease. Using PM, scientists have managed to discover the two major predictive makers of breast cancer and these include estrogen receptor (ER) and human epidermal growth factor (HER2). This understanding has helped scientists come up with targeted therapy depending on the type of maker present and more information click here.
Determining Drug Effectiveness in Humans
Through the years, precision medicine has made significant milestones in helping scientists find a cure for different types of cancer. Oncotarget, on the other hand, has concentrated on publishing research relevant to oncology and what Oncotarge knows. One of the recent publications was a research done by Norris Cotton Cancer Center led by Alan Eastman. The research focused on drugs tried on mice worked with the same mechanism in humans. The researchers used cancer drug gemcitabine for both animal and human models. In their research, the team was able to determine the mechanism in which the drug works when treating cancer in humans and Oncotarget lacrosse camp.
Oncotarget is a peer-reviewed open access weekly medical journal covering oncology. The journal was established in 2010 and over the years, the journal, which is published by Impact Journals, has published several articles that help cancer treatment research. Mikhail Blagosklonny and Andrei V. Gudkov are the chief editors. Scientists are free to submit their research to the journal, but you have to ensure that your article meets all the publication ethics and Oncotarget on Facebook.
More Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex